- Home
- KREF vs EBS Comparison
KREF vs EBS Comparison
Compare KREF & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KREF
- EBS
- Stock Information
- Founded
- KREF 2014
- EBS 1998
- Country
- KREF United States
- EBS United States
- Employees
- KREF N/A
- EBS N/A
- Industry
- KREF Real Estate Investment Trusts
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- KREF Real Estate
- EBS Health Care
- Exchange
- KREF Nasdaq
- EBS Nasdaq
- Market Cap
- KREF 623.9M
- EBS 529.9M
- IPO Year
- KREF 2017
- EBS 2006
- Fundamental
- Price
- KREF $8.24
- EBS $10.98
- Analyst Decision
- KREF Buy
- EBS Strong Buy
- Analyst Count
- KREF 6
- EBS 2
- Target Price
- KREF $10.71
- EBS $13.50
- AVG Volume (30 Days)
- KREF 829.2K
- EBS 1.4M
- Earning Date
- KREF 10-21-2025
- EBS 10-29-2025
- Dividend Yield
- KREF 12.08%
- EBS N/A
- EPS Growth
- KREF N/A
- EBS N/A
- EPS
- KREF N/A
- EBS 1.35
- Revenue
- KREF $62,012,000.00
- EBS $788,900,000.00
- Revenue This Year
- KREF $16.86
- EBS N/A
- Revenue Next Year
- KREF N/A
- EBS $15.42
- P/E Ratio
- KREF N/A
- EBS $8.06
- Revenue Growth
- KREF N/A
- EBS N/A
- 52 Week Low
- KREF $7.78
- EBS $4.02
- 52 Week High
- KREF $12.06
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- KREF 44.81
- EBS 57.32
- Support Level
- KREF $7.78
- EBS $9.71
- Resistance Level
- KREF $8.15
- EBS $11.01
- Average True Range (ATR)
- KREF 0.21
- EBS 0.80
- MACD
- KREF -0.00
- EBS -0.01
- Stochastic Oscillator
- KREF 47.39
- EBS 40.60
About KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.